tbuckley/cabot-search huggingface dataset:
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Authors: Valsamo Anagnostou, Noushin Niknafs, Kristen Marrone, Daniel C. Bruhm, James R. White, Jarushka Naidoo, Karlijn Hummelink, Kim Monkhorst, Ferry Lalezari, Mara Lanis, Samuel Rosner, Joshua E. Reuss, Kellie N. Smith, Vilmos Adleff, Kristen Rodgers, Zineb Belcaid, Lamia Rhymee, Benjamin Levy, Josephine Feliciano, Christine L. Hann, David S. Ettinger, Christos Georgiades, Franco Verde, Peter Illei, Qing Kay Li, Alexander S. Baras, Edward Gabrielson, Malcolm V. Brock, Rachel Karchin, Drew M. Pardoll, Stephen B. Baylin, Julie R. Brahmer, Robert B. Scharpf, Patrick M. Forde, Victor E. Velculescu
Journal: Nature Cancer (2020)
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
Authors: Nobuhiko Kanaya, Shinji Kuroda, Yoshihiko Kakiuchi, Kento Kumon, Tomoko Tsumura, Masashi Hashimoto, Toshiaki Morihiro, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Hiroyuki Mizuguchi, Yasuo Urata, Toshiyoshi Fujiwara
Journal: Molecular Therapy (2020)

The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), the safety of which was confirmed in a phase I clinical study. Here, we examined the potential of OBP-502, an OBP-301 variant, as an agent for inducing immunogenic cell death (ICD) and synergistically enhancing the efficacy of OBP-502 with PD-1 Ab using CT26 murine colon cancer and PAN02 murine pancreatic cancer cell lines. OBP-502 induced the release of ICD molecules such as adenosine triphosphate (ATP) and high-mobility group box protein 1 (HMGB1) from CT26 and PAN02 cells, leading to recruitment of CD8-positive lymphocytes and inhibition of Foxp3-positive lymphocyte infiltration into tumors. Combination therapy involving OBP-502 intratumoral administration and PD-1 Ab systemic administration significantly suppressed the growth of not only OBP-502-treated tumors but also tumors not treated with OBP-502 (so-called abscopal effect) in CT26 and PAN02 bilateral subcutaneous tumor models, in which active recruitment of CD8-positve lymphocytes was observed even in tumors not treated with OBP-502. This combined efficacy was similar to that observed in a CT26 rectal orthotopic tumor model involving liver metastases. In conclusion, telomerase-specific oncolytic adenoviruses are promising candidates for combined therapies with ICIs.
Surveillance of Adolescents and Young Adult Patients with Fanconi Anemia (FA): Awareness of Diagnosing Solid Tumors at a Young Age
Authors: J. Balmana, N. Bosch, N. Gadea, C. Heredia, T. Olive, D. Valcárcel, M. Munill, C. Centeno, J.L. Quesada, J. Surralles
Journal: Annals of Oncology (2012)
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
Authors: Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, Matthias Kloor, Anna‐Lena Volckmar, Volker Endris, Ivo Buchhalter, Albrecht Stenzinger, Krzysztof Grzyb, Marit M. Grimsrud, Barbara Gornicka, Erik von Seth, Gary M. Reynolds, Andre Franke, Daniel N. Gotthardt, Arianeb Mehrabi, Angela Cheung, Joanne Verheij, Johanna Arola, Heikki Mäkisalo, Tor J. Eide, Sören Weidemann, John C. Cheville, Giuseppe Mazza, Gideon M. Hirschfield, Cyriel Y. Ponsioen, Annika Bergquist, Piotr Milkiewicz, Konstantinos N. Lazaridis, Christoph Schramm, Michael P. Manns, Martti Färkkilä, Arndt Vogel, Kirsten M. Boberg, Peter Schirmacher, Tom H. Karlsen
Journal: Hepatology (2020)

Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC. To open new avenues for management, we aimed to delineate clinically relevant genomic and pathological features of a large panel of PSC-associated BTC (PSC-BTC).We analyzed formalin-fixed, paraffin-embedded tumor tissue from 186 patients with PSC-BTC from 11 centers in eight countries with all anatomical locations included. We performed tumor DNA sequencing at 42 clinically relevant genetic loci to detect mutations, translocations, and copy number variations, along with histomorphological and immunohistochemical characterization. Regardless of the anatomical localization, PSC-BTC exhibited a uniform molecular and histological characteristic similar to extrahepatic cholangiocarcinoma. We detected a high frequency of genomic alterations typical of extrahepatic cholangiocarcinoma, such as TP53 (35.5%), KRAS (28.0%), CDKN2A (14.5%), and SMAD4 (11.3%), as well as potentially druggable mutations (e.g., HER2/ERBB2). We found a high frequency of nontypical/nonductal histomorphological subtypes (55.2%) and of the usually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%).Genomic alterations in PSC-BTC include a significant number of putative actionable therapeutic targets. Notably, PSC-BTC shows a distinct extrahepatic morpho-molecular phenotype, independent of the anatomical location of the tumor. These findings advance our understanding of PSC-associated cholangiocarcinogenesis and provide strong incentives for clinical trials to test genome-based personalized treatment strategies in PSC-BTC.
Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)
Authors: A.X. Zhu, O. Rosmorduc, J. Evans, P. Ross, A. Santoro, F.J. Carrilho, M. Leberre, M. Jensen, G. Meinhardt, Y. Kang
Journal: Annals of Oncology (2012)
A Randomised Phase III Clinical trial of Combined Therapy with CPT-11/CDDP versus CPT-11 alone in Patients with advanced or Recurrent Gastric Cancer Resistant to S-1(Trics Study): Safety Analysis
Authors: H. Hasegawa, K. Nishikawa, H. Inagaki, S. Akamaru, S. Tokunaga, M. Takagi, S. Tamura, S. Morita, J. Sakamoto, T. Tsujinaka
Journal: Annals of Oncology (2012)
Mutations in the Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer Patients and Egfr Serum Levels
Authors: E.Y. Romero-Ventosa, M. Rodríguez Rodríguez, S. Gonzalez Costas, A. GonzÁlez-PiÑeiro, S. Blanco-Prieto, M. Páez de La Cadena, I. Arias Santos, B. Leboreiro Enriquez, B. Bernardez Ferran, E. Brozos
Journal: Annals of Oncology (2012)
Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population
Authors: Shipra Arya, Taylor A. Melanson, Elizabeth L. George, Kara A. Rothenberg, Manjula Kurella Tamura, Rachel E. Patzer, Jason M. Hockenberry
Journal: Journal of the American Society of Nephrology (2020)

Significance Statement Of incident hemodialysis patients in the United States, 80% start hemodialysis on a central venous catheter (CVC). Despite a national push toward arteriovenous fistula and arteriovenous graft use, little is known about the characteristics and natural history of patients who start hemodialysis on a CVC. In an observational cohort study analyzing data from the US Renal Data System for such patients, the authors found that time on a CVC was longer among women compared with men and among black patients compared with whites and other races/ethnicities. Female and black patients also transitioned to arteriovenous fistula less frequently than their counterparts. Strategies to promote more timely transitions to permanent access should focus on groups that lag in transitioning from a CVC to permanent access. Background Despite efforts to increase arteriovenous fistula and graft use, 80% of patients in the United States start hemodialysis on a central venous catheter (CVC). Methods To better understand in incident hemodialysis patients how sex and race/ethnicity are associated with time on a central venous catheter and transition to an arteriovenous fistula and graft, our observational cohort study analyzed US Renal Data System data for patients with incident ESKD aged ≥66 years who started hemodialysis on a CVC in July 2010 through 2013. Results At 1 year, 32.7% of 74,194 patients transitioned to an arteriovenous fistula, 10.8% transitioned to an arteriovenous graft, 32.1% stayed on a CVC, and 24.5% died. Women spent a significantly longer time on a CVC than men. Compared with white patients, patients who were black, Hispanic, or of another racial/ethnicity minority spent significantly more days on a CVC. In competing risk regression, women were significantly less likely than men to transition to a fistula and more likely to transition to a graft. Compared with white patients, blacks were significantly less likely to transition to a fistula but more likely to transition to a graft, Hispanics were significantly more likely to transition to a fistula, and other races/ethnicities were significantly more likely to transition to either a fistula or a graft. Conclusions Female patients spend a longer time on a CVC and are less likely to transition to permanent access. Compared with white patients, minorities also spend longer time on a CVC, but are more likely to eventually transition to permanent access. Strategies to speed transition to permanent access should target groups that currently lag in this area.
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells
Authors: Anna Śledzińska, Maria Vila de Mucha, Katharina Bergerhoff, Alastair Hotblack, Dafne Franz Demane, Ehsan Ghorani, Ayse U. Akarca, Maria A.V. Marzolini, Isabelle Solomon, Frederick Arce Vargas, Martin Pule, Masahiro Ono, Benedict Seddon, George Kassiotis, Charlotte E. Ariyan, Thomas Korn, Teresa Marafioti, Graham M. Lord, Hans Stauss, Richard G. Jenner, Karl S. Peggs, Sergio A. Quezada
Journal: Immunity (2020)

In addition to helper and regulatory potential, CD4
Breast Cancer Patients with Her2neu Overexpression: Relationship among Clinicopathological Characteristics and Local/Distant Recurrences and Survival
Authors: C. Bellido-Ribes, S. Gonzalez, A. Garcia, V. Obadia, R. Bastus, J. Fernández, A. Aguilar, L. Cirera
Journal: Annals of Oncology (2012)
β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade
Authors: Fang Zhang, Mary Gannon, Yunjia Chen, Shun Yan, Sixue Zhang, Wendy Feng, Jiahui Tao, Bingdong Sha, Zhenghui Liu, Takashi Saito, Takaomi Saido, C. Dirk Keene, Kai Jiao, Erik D. Roberson, Huaxi Xu, Qin Wang
Journal: Science Translational Medicine (2020)

Noradrenergic signaling sensitizes pathological GSK3β/tau activation to nanomolar Aβ.
Impact of FCGR2A and FCGR3A Polymorphisms on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab and Folfiri as 2nd-Line Therapy
Authors: I. Yuka, S. Hazama, N. Okayama, Y. Hinoda, H. Mishima, J. Sakamoto, Y. Miyake, S. Iwamoto, F. Goda, M. Oka
Journal: Annals of Oncology (2012)
ATRT-03. MALIGNANT RHABDOID TUMORS ORIGINATING WITHIN AND OUTSIDE THE CENTRAL NERVOUS SYSTEM ARE CLINICALLY AND MOLECULARLY HETEROGENEOUS
Authors: Emilia Pinto, Dima Hamideh, Armita Bahrami, Brent Orr, Tong Lin, Stanley Pounds, Gerard Zambetti, Alberto Pappo, Sameer Agnihotri, Amar Gajjar, Alberto Broniscer
Journal: Neuro-Oncology (2018)

Multifocal synchronous/metachronous ATRTs and extra-CNS MRTs are rare. We reviewed clinicoradiologic characteristics of affected patients. Genotyping and copy number abnormality (CNA) analysis in SMARCB1 were performed in germline and tumor samples. Tumor samples underwent DNA methylation and CNA analysis. Median age at diagnosis (n=21 patients) was 0.6 years. Two-thirds of patients had synchronous tumors. Although kidney tumors predominated, at least 30% of cases lacked renal involvement. Histopathologic review confirmed MRTs in all cases and INI1 expression loss in all tumors tested. Fourteen (78%) of 18 patients tested had heterozygous germline SMARCB1 abnormalities. Mono and biallelic SMARCB1 abnormalities were confirmed in at least 50% and 80% of tumors, respectively. Unsupervised hierarchical clustering analysis of DNA methylation in 27 tumors and comparison to 150 reference ATRTs classified 14 multifocal ATRTs as SHH (64%), tyrosinase (21%), and MYC (14%). The MYC subgroup accounted for 85% of 13 extra-CNS MRTs. Of 16 paired ATRTs and extra-CNS MRTs, 7 of 8 patients had tumors with different patterns of DNA methylation and/or CNAs suggestive of non-clonal origin. CNS and extra-CNS tumors had an identical SMARCB1 amplification (n=1) or similar DNA methylation pattern (n=1) suggestive of clonal origin. All patients died of tumor progression. The clinical and molecular characteristics of multifocal ATRTs and extra-CNS MRTs are heterogeneous with most patients harboring a cancer predisposition. Although independent tumor origin was confirmed in most cases, metastatic spread was also documented. The recognition of their distinct molecular characteristics is critical in selecting new biologic therapies against these deadly cancers.
Prophylaxis of Catheter-Related Deep Vein Thrombosis in Cancer Patients with Low-Dose Warfarin, Low Molecular Weight Heparin, or Control: A Randomized, Controlled, Phase III Study
Authors: S. Lavau-Denes, P. Lacroix, A. Maubon, P. Preux, D. Genet, L. Venat-Bouvet, J. Labourey, J. Martin, P. Slaouti, N. Tubiana-Mathieu
Journal: Annals of Oncology (2012)
Correlation Between the Effects of First-Line Chemotherapy and Survival Time from Second-Line Chemotherapy in Patients with Advanced Gastric Cancer
Authors: H. Tabuse, H. Yasui, T. Funakoshi, S. Hamauchi, T. Tsushima, H. Taniguchi, A. Todaka, T. Yokota, N. Machida, K. Yamasaki, A. Fukutomi, Y. Onozawa, N. Boku
Journal: Annals of Oncology (2012)
Th2A and Th17 cell frequencies and regulatory markers as follow‐up biomarker candidates for successful multifood oral immunotherapy
Authors: Sonia Luce, Sharon Chinthrajah, Shu-Chen Lyu, Kari C. Nadeau, Laurent Mascarell
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma.
Authors: Theodoros Nicholas Teknos, Matthew Owen Old, John C. Grecula, Amit Agrawal, Enver Ozer, Ricardo Carrau, Stephan Kang, James William Rocco, Dukagjin Blakaj, Virginia Diavolitsis, Robert A. Baiocchi, Bhavna Kumar, Panayiotis Savvides
Journal: Journal of Clinical Oncology (2016)

6036 Background: Vorinostat (Zolinza) is a potent HDAC inhibitor that sensitizes head and neck squamous cell carcinoma (HNSCC) to cytotoxic therapy while sparing normal epithelium The primary objective of this study was to determine the maximally tolerated dose (MTD) of Vorinostat in combination with concurrent chemoradiation therapy. Secondary and tertiary endpoints included therapeutic response and delineation of acute and late toxicities. Methods: Twenty seven of 29 consented patients with Stage III/IV unresectable HNSCC completed the protocol. Patients received Vorinostat in combination with standard cisplatin/carboplatin chemotherapy (every 21 days) and intensity modulated radiation therapy (IMRT, 70Gy). Doses of Vorinostat were escalated in sequential cohorts of three patients. Toxicities were determined using standard NCI-CTCAEv4.03. Dose limiting toxicities (DLT) were defined as any adverse event of Grade 3 or higher. Results: Of the 27 patients on this study, 17/27 were p16/HPV+. The MTD of Vorinostat was 200mg delivered on M,W,F in combination with concurrent chemoradiation therapy. Twenty five of 27 patients (92.59%) had a complete response (CR) to therapy and 24/27 (88.89%) are alive and disease-free at a mean follow-up of 32.1 months (range 2-66 months). Two patients (7.41%) had residual disease at the completion of therapy and died of disease. One patient had a CR but developed lung metastases at 12 months. He is currently alive with disease at 38 months. The regimen was well tolerated and resulted in no treatment breaks during radiotherapy. Patients experienced a mean weight loss of 11.69% (range 0.79-20.61%) along with low rates of radiation related dermatitis (22/27 Grade 1) and oral mucositis (0/27 Grade 4, 15/27 Grade 3, 6/27 Grade 2, 6/27 Grade 1). No patient developed osteoradionecrosis, 4/27 developed pharyngeal stenosis and 1/27 developed Grade 3 xerostomia. Conclusions: Vorinostat in combination with concurrent chemoradiation therapy is a safe and highly effective treatment regimen. There was a high rate of complete response to therapy with toxicity rates comparable, if not more favorable, to existing treatment standards. Clinical trial information: NCT01064921.
Predictive Value of Circulating Endothelial Cell (CEC) Levels in Metastatic or Locally Advanced Neuroendocrine Digestive Tumor Patients Treated With Chemotherapy and Bevacizumab
Authors: F.F. Farace, C. Lombard-Bohas, E. Mitry, M. Ychou, L. Bengrine-Lefevre, T. Lecomte, K. Joly, M. Ducreux, E. Baudin
Journal: Annals of Oncology (2012)
Phase 1 Dose-Escalation Trial of the Investigational Hedgehog (HH) Pathway Inhibitor Tak-441 in Patients with Advanced Solid Tumors
Authors: J.W. Goldman, S.G. Eckhardt, M. Borad, M. Hidalgo, D.P. Ryan, A. Parikh, S. Kuan, J. Yu, S. Stewart, L.S. Rosen
Journal: Annals of Oncology (2012)
P-0268 Notch and DLL4 Expression in Colon Cancer Patients Treated with Bevacizumab
Authors: Francesca V. Negri, Cecilia Bozzetti, Costanza Lagrasta, Pellegrino Crafa, Stefano Cavalli, Giuseppe Pedrazzi, Rosa Porzio, Gianpaolo Bacchini, Luigi Cavanna, Carlo Paties, Andrea Ardizzoni
Journal: Annals of Oncology (2012)
Induction Therapy with Cetuximab, Docetaxel, Cisplatin, and Fluorouracil in Patients with Resectable Non Metastatic Stage III or IV Squamous Cell Carcinoma of the Oropharynx. A Gercor Phase II Study
Authors: B. Chibaudel, R. Lacave, J. Belloc, A. Banal, S. Albert, F. Chabolle, M. Lefevre, P. Soussan, R. Moukoko, J. Lacau Saint Guily
Journal: Annals of Oncology (2012)
Absence of GP130 cytokine receptor signaling causes extended Stüve-Wiedemann syndrome
Authors: Yin-Huai Chen, Giedre Grigelioniene, Phillip T. Newton, Jacob Gullander, Maria Elfving, Anna Hammarsjö, Dominyka Batkovskyte, Hessa S. Alsaif, Wesam I.Y. Kurdi, Firdous Abdulwahab, Veerabahu Shanmugasundaram, Luke Devey, Séverine Bacrot, Jana Brodszki, Celine Huber, Ben Hamel, David Gisselsson, Nikos Papadogiannakis, Katarina Jedrycha, Barbara Gürtl-Lackner, Andrei S. Chagin, Gen Nishimura, Dominik Aschenbrenner, Fowzan S. Alkuraya, Arian Laurence, Valérie Cormier-Daire, Holm H. Uhlig
Journal: The Journal of Experimental Medicine (2020)

The gene IL6ST encodes GP130, the common signal transducer of the IL-6 cytokine family consisting of 10 cytokines. Previous studies have identified cytokine-selective IL6ST defects that preserve LIF signaling. We describe three unrelated families with at least five affected individuals who presented with lethal Stüve-Wiedemann–like syndrome characterized by skeletal dysplasia and neonatal lung dysfunction with additional features such as congenital thrombocytopenia, eczematoid dermatitis, renal abnormalities, and defective acute-phase response. We identified essential loss-of-function variants in IL6ST (a homozygous nonsense variant and a homozygous intronic splice variant with exon skipping). Functional tests showed absent cellular responses to GP130-dependent cytokines including IL-6, IL-11, IL-27, oncostatin M (OSM), and leukemia inhibitory factor (LIF). Genetic reconstitution of GP130 by lentiviral transduction in patient-derived cells reversed the signaling defect. This study identifies a new genetic syndrome caused by the complete lack of signaling of a whole family of GP130-dependent cytokines in humans and highlights the importance of the LIF signaling pathway in pre- and perinatal development.
Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling
Authors: Melissa K. Frey, Ryan M. Kahn, Eloise Chapman-Davis, Francesca Tubito, Maira Pires, Paul Christos, Samantha Anderson, Semanti Mukherjee, Bailey Jordan, Stephanie V. Blank, Thomas A. Caputo, Ravi N. Sharaf, Kenneth Offit, Kevin Holcomb, Steven Lipkin
Journal: Journal of Clinical Oncology (2020)

PURPOSE A powerful consequence of detecting cancer-associated pathogenic variants is the ability to test at-risk relatives (ARRs), termed cascade testing. However, historical studies suggest cascade testing uptake of 30% or less. Here, we tested the feasibility of a novel, streamlined method of cascade testing using telephone genetic counseling and mailed saliva-based genetic testing. PATIENTS AND METHODS Probands with newly diagnosed cancer-associated pathogenic variants were offered facilitated cascade testing whereby the genetics team identified and contacted ARRs by telephone to disclose the familial pathogenic variant and offer telephone counseling and mailed saliva testing. Results and guideline-based recommendations were reviewed by telephone and shared with the primary care physician. RESULTS Thirty probands were enrolled, and 114 ARRs were identified. Twelve ARRs were excluded (lived outside of the United States, n = 5; proband did not approve of contact, n = 7). Among 102 ARRs telephoned, contact was established with 95 (93%). Among 114 identified ARRs, 66 (58%) completed genetic testing. Among those completing testing, 27 (41%) carried the familial pathogenic variant. Surveys of ARRs at the time of genetic testing and 6 months later demonstrated low levels of anxiety, depression, distress, and uncertainty and high levels of satisfaction with testing. At 6 months, 7 ARRs with pathogenic variants had undergone cancer surveillance interventions and 4 had undergone cancer risk-reducing surgery. CONCLUSION Facilitated cascade testing with telephone genetic counseling and mailed saliva kits resulted in high testing uptake among ARRs. Positive genetic testing resulted in utilization of genetically targeted primary disease prevention at short-term follow-up. Facilitated cascade testing is a straightforward, low-cost, easily implemented strategy with significant potential to promote early detection for affected ARRs and reduce cancer mortality and should be evaluated in larger scale clinical trials.
Nature-derived compounds modulating Wnt/ -catenin pathway: a preventive and therapeutic opportunity in neoplastic diseases
Authors: Gianluca Sferrazza, Marco Corti, Gloria Brusotti, Pasquale Pierimarchi, Caterina Temporini, Annalucia Serafino, Enrica Calleri
Journal: Acta Pharmaceutica Sinica B (2020)

The Wnt/β-catenin signaling is a conserved pathway that has a crucial role in embryonic and adult life. Dysregulation of the Wnt/β-catenin pathway has been associated with diseases including cancer, and components of the signaling have been proposed as innovative therapeutic targets, mainly for cancer therapy. The attention of the worldwide researchers paid to this issue is increasing, also in view of the therapeutic potential of these agents in diseases, such as Parkinson's disease (PD), for which no cure is existing today. Much evidence indicates that abnormal Wnt/β-catenin signaling is involved in tumor immunology and the targeting of Wnt/β-catenin pathway has been also proposed as an attractive strategy to potentiate cancer immunotherapy. During the last decade, several products, including naturally occurring dietary agents as well as a wide variety of products from plant sources, including curcumin, quercetin, berberin, and ginsenosides, have been identified as potent modulators of the Wnt/β-catenin signaling and have gained interest as promising candidates for the development of chemopreventive or therapeutic drugs for cancer. In this review we make an overview of the nature-derived compounds reported to have antitumor activity by modulating the Wnt/β-catenin signaling, also focusing on extraction methods, chemical features, and bio-activity assays used for the screening of these compounds.